Ovarian Neoplasms Clinical Trial
Official title:
Gynacological Imaging Reporting and Data System in Classifying Ovarian Masses on the Basis of Ultrasonography
Ovarian masses are common problems in clinical practice. Sonography is considered the firstline imaging technique for discriminating between malignant and benign lesions, and it has been shown to be useful for determining optimal treatment.
Transvaginal Ultrasonography has been demonstrated to be the most sensitive and effective
technique, being also non-invasive and in-expensive maneuver.Since in early reports, a
standardized method for the description of the sonographic appearance of the ovarian masses
was not used, the data of different studies are not easily compared.
In addition, there is no consensus on sonographic diagnostic criteria for ovarian cancer,
despite many ultrasonography features being considered to be predictive of malignancy, such
as presence of septations, internal nodularity, wall thickening, solid areas, free fluid or
bilaterality.Usually the clinical management decision is based on data provided in the
sonographic report. Many sonographers and sonologists use scoring systems to characterize
ovarian masses, whereas others use the so called pattern recognition approach However,
sometimes sonographic reports are misleading and confusing for the clinician. Although some
groups have made considerable efforts in establishing terms and definitions for sonographic
findings in ovarian masses .
In this study, we proposed a new data reporting system for sonographic findings in ovarian
masses. This system is based on the concept developed for breast imaging, namely the Breast
Imaging Reporting and Data System classification. Originally developed for mammographic
findings, it has been successfully applied to breast sonography.
Like its breast sonographic counterpart, the gynacological imaging reporting and data system
in ovarian masses by ultrasonography lexicon is intended to provide a unified language for
sonographic reporting and for avoiding confusion in communication between the sonographer /
sonologist and the clinician..
This system is based on a description of the ovarian mass using the pattern recognition
approach and color Doppler blood flow location and the prior risk for malignancy in each
group. On this basis, the proposed classification enables the sonologist or sonographer to
give the clinician as much information as possible in a summarized way, as well as an
estimated risk of malignancy, based only on the sonographic characteristics of the images.
Currently, there is enough evidence to indicate that when an experienced examiner performs
the sonographic examination, such accuracy is achievable for most types of ovarian masses.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02569983 -
The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
|
||
Withdrawn |
NCT02243059 -
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
|
Phase 4 | |
Terminated |
NCT02055690 -
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT00415181 -
Pharmacogenomics of Paclitaxel in Ovarian Cancer
|
N/A | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|
||
Completed |
NCT00772863 -
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00069160 -
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
|
Phase 2 | |
Completed |
NCT00046800 -
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00035100 -
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
|
Phase 2 | |
Terminated |
NCT00034372 -
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT00001272 -
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Completed |
NCT02227654 -
Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 |